Pharmaceutical intelligence for Mirati Therapeutics with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Assets: 1

Recent signals(1)

ClinicalJuly 18, 2026

Mirati's Adagrasib Plus Pembrolizumab Trial for NSCLC Shows Promise

A trial is underway to assess the combination of adagrasib, pembrolizumab, and chemotherapy in KRAS G12C mutated NSCLC.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity

No signals indexed for this entity yet.

Clinical activity(1)

ClinicalJuly 18, 2026

Mirati's Adagrasib Plus Pembrolizumab Trial for NSCLC Shows Promise

A trial is underway to assess the combination of adagrasib, pembrolizumab, and chemotherapy in KRAS G12C mutated NSCLC.

Competitive activity

No signals indexed for this entity yet.

Assets

Adagrasib →

Therapeutic areas

NSCLC →

Oncology →

Indications

NSCLC →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.